Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given
together with R-(-)-gossypol acetic acid and to see how well they work in treating patients
with B-cell chronic lymphocytic leukemia (B-CLL) that has returned after a period of
improvement (relapsed). Biological therapies, such as lenalidomide, may stimulate the immune
system to attack cancer cells. R-(-)-gossypol acetic acid may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth and causing the cells to die. Giving
lenalidomide with R-(-)-gossypol acetic acid may be an effective treatment for relapsed or
refractory B-CLL. - Funding Source - FDA OOPD